FDA will require 50% efficacy for COVID-19 vaccines, WSJ says. How high is that bar? Humana to offer home COVID-19 testing, drive-thru testing at Walmart Covance links up COVID-19 trial tool to help research get back underway With more nays than yays for Gilead's remdesivir pricing, are pharma's rep gains sunk? Trinity Health projects $2B revenue loss in 2021 due to COVID-19 as furloughs and layoffs extended Twist Bioscience launches research panel for screening COVID-19, other respiratory viruses Novavax hires new manufacturing chief to take COVID-19, flu vaccine hopefuls across the finish line More than 300 organizations, physician groups push Congress to take action on telehealth policies Biopharma roundup: AbbVie HIV med falls short in trial; Mexico in talks with China, AZ for COVID-19 tests Healthcare roundup: Fauci 'wouldn't be surprised' U.S. hit 100K cases a day Featured Story | By Eric Sagonowsky Coronavirus vaccine developers now have some advice from the U.S. FDA. To win an approval, any vaccine must be at least 50% more effective than placebo in preventing the disease, the WSJ reports, citing guidance to be presented today. That's about as effective as a flu shot in a good year—but it falls short of some expert recommendations for arresting the virus' spread. read more |
| |
|---|
|
Top Stories By Paige Minemyer Humana will now offer LabCorp’s home COVID-19 tests to its members and is teaming up with Walmart and Quest Diagnostics to provide access to drive-thru tests. read more By Ben Adams LabCorp’s CRO unit Covance has updated its Xcellerate platform to seek out as well as help restore and continue ongoing trials hit by the pandemic. read more By Beth Snyder Bulik After months of waiting, Gilead’s pricing for COVID-19 treatment remdesivir inspired the backlash many expected. Patient advocacy groups and legislators howled over the $3,120 price tag as greedy and excessive, while analysts and even an industry watchdog pegged the price as acceptable—and in some cases, lower than expected. read more By Robert King Trinity Health announced it will lose $2 billion in operating revenue in 2021 due to COVID-19 and it will extend furloughs and lay off more workers. read more By Conor Hale Synthetic DNA manufacturer Twist Bioscience launched a new research panel focused on identifying respiratory diseases, including the novel coronavirus behind the COVID-19 pandemic. read more By Kyle Blankenship With its COVID-19 vaccine hopeful cycling through clinical trials, shot maker Novavax is working to flesh out its executive team to help lead the company to the commercial stage. But you can't get regulatory approval without a sturdy manufacturing operation—and now Novavax has appointed an exec to get that house in order. read more By Heather Landi Healthcare industry groups are pushing congressional leaders to pass new legislation that will permanently expand telehealth flexibilities. Find out what specific steps the national and regional organizations want Congress to take to expand telehealth. read more by Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner AbbVie's common HIV med Kaletra failed to slash death rates in a U.K. trial. Inovio turned in strong interim data on its DNA vaccine candidate. Mexico wants COVID trials in-country, and it's in talks with China and AstraZeneca to make it happen. The FDA has new vaccine approval guidance, and Fauci plans to testify before Congress again. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more | | [Webinar] Mastering the Virtual Clinical Trial Now available on demand! This Fierce webinar will bring together executives with expertise in R&D and technology implementation to explain the potential benefits of virtual clinical trials, as well as the ins and outs of designing and running them. It will include representatives from companies that have completed virtual clinical trials successfully and can provide advice on what did and did not work. Watch now. |
|
